Last reviewed · How we verify

NCT04351009

Sentinel Lymph Node Mapping and Analysis in Colon Cancer Using Indocyanine Green Dye

Completed NA Last updated 6 July 2022
What this trial tests

NA trial testing sentinel lymph node mapping in Colon Cancer in 48 participants. Completed in 30 June 2022.

Timeline
8 June 2020
Primary endpoint
30 June 2022
30 June 2022

Quick facts

Lead sponsorAsian Institute of Gastroenterology, India
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment48
Start date8 June 2020
Primary completion30 June 2022
Estimated completion30 June 2022
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Asian Institute of Gastroenterology, India

Who can join

Adults 18 to 80, any sex, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 20-30 % of colon cancer patients who have no metastasis in lymph nodes after definitive colectomy have recurrence with distant metastasis. These recurrences could be due to missed occult tumor cells or micrometastasis. Detailed examination of all lymph nodes is expensive and time consuming. Sentinel lymph node mapping using Indocyanine green dye helps in identifying the lymph nodes which are most likely to harbour metastasis. These sentinel lymph nodes can be subsequently subjected to detailed pathologic examination and immunohistochemistry which increases the likelihood of identifying micrometastasis and occult tumor cells. Patients found to harbour such metastasis can be treated with additional chemotherapy after surgery. The aim of the study is to examine the feasibility of sentinel lymph node mapping using Indocyanine green dye in colon cancer and evaluate the upstaging rate in post-operative colon cancer patients who don't have metastatic lymph nodes on routine histopathology.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Crosstalk between Wnt/β-catenin signaling pathway and DNA damage response in cancer: a new direction for overcoming therapy resistance.
    Zhang X, Yu X. · · 2023 · cited 19× · PMID 37601042 · DOI 10.3389/fphar.2023.1230822
  2. Pharmacological targeting of the novel β-catenin chromatin-associated kinase p38α in colorectal cancer stem cell tumorspheres and organoids.
    Lepore Signorile M, Grossi V, Di Franco S, Forte G, et al · · 2021 · cited 19× · PMID 33767160 · DOI 10.1038/s41419-021-03572-4
  3. Indocyanine green guided sentinel lymph node biopsy may have a high sensitivity for early (T1/T2) colon cancer: A prospective study in Indian patients.
    Ahmed Z, Patil SM, Sekaran A, Rebala P, et al · · 2023 · cited 5× · PMID 38058374 · DOI 10.47717/turkjsurg.2023.6106

Verify or expand the search:

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

Other Asian Institute of Gastroenterology, India trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing